Loading...
•
Mar 31, 2024
Aura Biosciences Q1 2024 Earnings Report
Aura Biosciences reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.
Key Takeaways
Aura Biosciences reported a net loss of $19.7 million for the first quarter of 2024. As of March 31, 2024, the company's cash and cash equivalents and marketable securities totaled $202.9 million, which is expected to fund operations into the second half of 2026. Enrollment continues in the global Phase 3 CoMpass trial for choroidal melanoma, and early Phase 1 data from the bladder cancer trial is expected mid-2024.
Enrollment continues in the global Phase 3 CoMpass trial for the treatment of small choroidal melanoma and indeterminate lesions.
Aura expects early Phase 1 data from its bladder cancer trial in mid-2024.
Cash and cash equivalents and marketable securities totaled $202.9 million as of March 31, 2024.
Aura believes its current cash is sufficient to fund operations into the second half of 2026.
Forward Guidance
Aura Biosciences believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into the second half of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...